First Human Subject Enrolled in Lumosa Therapeutics’ LT3001 Trial


July 31, 2017 (STL.News) LT3001 is a novel small molecule drug for the treatment of acute ischemic stroke. In animal studies, LT3001 can restore blood flow, reduce cerebral infarct volume, and improve neurological outcome in rodent and non-human primate stroke models, in which LT3001 showed an apparent wider therapeutic time window and a better safety [ ] The post First Human Subject Enrolled in Lumosa Therapeutics’ LT3001 Trial appeared first on STL News.
http://bit.ly/2uevfKM

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s